Ephedra warning letters
This article was originally published in The Tan Sheet
Universal Nutrition, which received FDA warning letter to discontinue ephedra athletic performance claims, says it has submitted response to agency pledging compliance and requesting clarification on some points; firm also has revised language on its Web site, labeling. New Brunswick, N.J.-based firm said it is debating whether or not to exit ephedra market. Other FDA letter recipients including American Body Building, Advanced Pharmaceuticals have issued similar responses to agency, which sent the letters in late February (1"The Tan Sheet" March 3, 2003, p. 8)...
You may also be interested in...
Athletic performance claims for ephedrine alkaloid-containing dietary supplements should be discontinued unless they can be scientifically supported, FDA states in Feb. 28 warning letters to 26 marketers
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.